Document Type
Original Article
Abstract
Background: Globally, colorectal cancer (CRC) ranks third in terms of cancer-related mortality for both sexes. More than 5.25 million persons globally (5-year prevalence) have colorectal cancer (CRC), which is marginally less common than breast cancer (7.79 million cancer cases).
Aim: To evaluate the sublocations (subgroups) according to different right cancer colon sites to justify the D3 right hemicolectomy according to different tumor locations.
Patients and methods: Between December 2021 and December 2023, a descriptive prospective study was carried out at the Surgical Oncology Department of Bab El-shaarya University Hospital, Al-Azhar University. Twenty patients, female and eleven males, met the criteria for right colon cancer and underwent treatment with D3 right hemicolectomy, as well as D3 extended right hemicolectomy to examine the distribution of lymph nodes in the mesocolon.
Results: Our study's most common tumor position is cecum, followed by hepatic flexure. The higher the grade, the higher the incidence of mesenteric LN involvement. The higher the preoperative radiological stage, the higher the incidence of mesenteric LN involvement.
Conclusion: The percentage of positive lymph nodes and the stage of the tumor are strongly correlated; of the 13 patients with a grade 2 diagnosis, 2 had positive lymph nodes (22.2 % of positive patients), and all seven patients with a grade 3 diagnosis (77.8% of positive patients) had positive lymph nodes with a high significant P-Value. Under the fascia overlying SMV and SMA, none of our patients had positive central LNs.
Keywords
Mesenteric Lymph Nodes; Right Colon Cancer; D3 Right Hemicolectomy
Subject Area
Onco-surgery
How to Cite This Article
Abdelghany, Mohamed Esmat; Al-Sheikh, Abd El-Fattah; and Embaby, Ahmed Mohamed Gouda
(2024)
"Evaluation of Mesenteric Lymph Nodes Affection in Right Colon Cancer during D3 Right Hemicolectomy,"
Al-Azhar International Medical Journal: Vol. 5:
Iss.
4, Article 57.
DOI: https://doi.org/10.58675/2682-339X.2401